Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
04:01pm, Tuesday, 05'th Aug 2025
Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; G
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
11:01am, Tuesday, 29'th Jul 2025
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
11:36am, Wednesday, 23'rd Jul 2025
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRN
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
01:11pm, Tuesday, 22'nd Jul 2025
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
10:45am, Tuesday, 22'nd Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme to Report Second Quarter 2025 Financial and Operating Results
08:30am, Tuesday, 22'nd Jul 2025
SAN DIEGO , July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, Au
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 16'th Jul 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)
04:33pm, Monday, 14'th Jul 2025
Halozyme Therapeutics, Inc.'s ENHANZE technology drives strong near-term growth, but its key patent expires in 2027, raising long-term sustainability concerns. MDASE, once seen as the next growth engi
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
10:51am, Thursday, 03'rd Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics Added to Russell 1000® Index
04:05pm, Monday, 30'th Jun 2025
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after marke
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:46am, Monday, 30'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme The
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
10:50am, Monday, 16'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:46am, Friday, 13'th Jun 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
12:36pm, Thursday, 05'th Jun 2025
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
